Please assess the completion status of the following clinical trial:

Trial Title: Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~For HAE: patient with a documented diagnosis of HAE:~* type I (from an antigenic deficiency of the C1 esterase inhibitor) or type II (from a functional deficiency of the C1 esterase inhibitor). The existence of a mutation in SERPING1 was not necessary for the inclusion~* HAE with normal C1-INH (ex type III) with a required mutation in FXII gene or with a typical family history of HAE diagnosed by a specialized physician belonging to CREAK network.~For AE resulting of mast cell activation: a documented diagnosis of AE resulting of mast cell activation included:~* mastocytosis,~* chronic spontaneous urticaria,~* acute urticaria after exposure of allergen during allergy challenge tests,~* mast cell activation syndrome.~For the control group:~* composed of patients who presented a stabilized disease (that was not infectious, not auto-inflammatory or inflammatory disease and without implication of endothelial cells).~Exclusion Criteria:~* Over 18 years or under 1 year.~* Diagnosis of HAE with a normal C1 esterase inhibitor or AE of unknown aetiology.~* Patients with HAE who received an acute attack treatment before the blood sample (the C1 esterase inhibitor concentrate or a bradykinin B2 receptor antagonist); patients with HAE who received a prophylactic treatment (danazol).~* Patients who were treated by omalizumab or corticosteroid treatment.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- patients with hereditary angioedema (Type: None): A blood sample will be performed in crisis and 7 days after the crisis.
- patients with angioedema resulting of mast cell activation (Type: None): A blood sample will be performed in crisis and 7 days after the crisis.
- healthy patients, without angioedema (Type: None): A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.

Based on this trial design, predict the completion outcome and termination type (if applicable).